Evidence map›Paper›PMID 41589252›Full record

ArticleInternational cancer conference journal2026

Pathological diagnosis and therapeutic management of hereditary leiomyomatosis and renal cell carcinoma syndrome-associated renal cell carcinoma.

Kojiro Tashiro, Yoji Nagashima, Mikiko Kaneko, Kana Harada, Chisen Takeuchi, Shun Sato, Haruka Matsuzawa, Hisashi Hasumi, Fumihiko Urabe, Shunsuke Tsuzuki and 6 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in International cancer conference journal, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors.

Kojiro TashiroDepartment of Urology, The Jikei University School of Medicine, 3-19-18, Nishi-Shimbashi, Minato-Ku, Tokyo, 105-0003 Japan.ORCID 0000-0002-4474-8972
Yoji NagashimaDepartment of Surgical Pathology, Tokyo Women's Medical University Graduate School of Medicine, Tokyo, Japan.
Mikiko KanekoDepartment of Clinical Genetics, The Jikei University Hospital, Tokyo, Japan.
Kana HaradaDepartment of Clinical Genetics, The Jikei University Hospital, Tokyo, Japan.
Chisen TakeuchiDepartment of Clinical Genetics, The Jikei University Hospital, Tokyo, Japan.
Shun SatoDepartment of Pathology, The Jikei University School of Medicine, Tokyo, Japan.
Haruka MatsuzawaDepartment of Pathology, The Jikei University School of Medicine, Tokyo, Japan.
Hisashi HasumiDepartment of Urology, Yokohama City University Graduate School of Medicine, Kanagawa, Japan.
Fumihiko UrabeDepartment of Urology, The Jikei University School of Medicine, 3-19-18, Nishi-Shimbashi, Minato-Ku, Tokyo, 105-0003 Japan.
Shunsuke TsuzukiDepartment of Urology, The Jikei University School of Medicine, 3-19-18, Nishi-Shimbashi, Minato-Ku, Tokyo, 105-0003 Japan.
Masaki HashimotoDepartment of Urology, The Jikei University School of Medicine, 3-19-18, Nishi-Shimbashi, Minato-Ku, Tokyo, 105-0003 Japan.
Kentaro YoshiharaDepartment of Urology, The Jikei University School of Medicine, 3-19-18, Nishi-Shimbashi, Minato-Ku, Tokyo, 105-0003 Japan.
Mariko HondaDepartment of Urology, The Jikei University School of Medicine, 3-19-18, Nishi-Shimbashi, Minato-Ku, Tokyo, 105-0003 Japan.
Hiroki YamadaDepartment of Urology, The Jikei University School of Medicine, 3-19-18, Nishi-Shimbashi, Minato-Ku, Tokyo, 105-0003 Japan.
Hiroshi KawameDepartment of Clinical Genetics, The Jikei University Hospital, Tokyo, Japan.
Takahiro KimuraDepartment of Urology, The Jikei University School of Medicine, 3-19-18, Nishi-Shimbashi, Minato-Ku, Tokyo, 105-0003 Japan.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Hereditary leiomyomatosis and renal cell carcinoma syndrome (HLRCC) is an autosomal dominant disorder caused by germline loss-of-function mutations in the Supplementary Information: The online version contains supplementary material available at 10.1007/s13691-025-00811-9.

Indexed as

Fumarate hydrataseHereditary leiomyomatosis and renal cell carcinoma syndromeLenvatinibPembrolizumabS-(2-succinyl) cysteine

Identifiers

PMID41589252
PMCPMC12831751

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.